ClinicalTrials.gg
RecruitingNCT04844684CORTABOUpdated Dec 23, 2025

Evaluation of Cortisol and Bile Acids Metabolism in Obese Patients

An observational study in Obesity, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by University Hospital, Lille · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Obesity by University Hospital, Lille — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University Hospital, Lille.

Planned enrollment
13th of 15
30 · median 134
Started
2023
the only one that year
Observational
15 of 23
3 open now
Registered
21st of 23
by date

Among the 23 studies in Obesity by University Hospital, Lille, this one is the 13th largest by planned enrollment of the 15 observational ones that give a count, is the only one that started in 2023, is one of 15 observational ones, and was the 21st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 23 studies in Obesity by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Obesity by University Hospital, Lille, or all of them as a file.
02

Study summary

Bariatric surgery is currently the most efficient treatment for obesity. The sustained weight loss and metabolic improvement seen following Roux-en-Y gastric bypass (RYGB), is explained partly by modifications in hormones including bile acids (BA). After RYGB, an increased total BA pool and a reduction in hepatic cortisol exposure is observed. Hydroxysteroid 11-β dehydrogenase 1 (HSD11B1), steroid 5α-reductases (SRD5A), and steroid 5β-reductases, AKR1D1 (also a BA metabolizing enzyme), are three enzymes involved in the metabolism of cortisol in the liver and are known to participate in metabolic syndrome. Their activity has been shown to be decreased after RYGB. Interestingly, the mechanisms explaining the modification of hepatic cortisol exposure and the activity of theses enzymes after RYGB are unknown. In view of the few data suggesting a link between cortisol metabolism and bile acids, this work aim to study and characterize this link in a context of RYBP

03

Conditions studied

  • Obesity

Keywords

  • Cortisol
  • Bile acids
  • Obesity
  • Bariatric surgery
  • Insulin resistance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients admitted for bariatric surgery in the department of endocrine surgery at Lille University Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-menopausal women
  • between 35 and 50 kg/m² included
  • Social insured
  • Ability to give consent

Exclusion criteria

Exclusion Criteria:

  • moderate and severe kidney insufficiency
  • hepatic insufficiency
  • known gallbladder lithiasis
  • history of cholecystectomy or cholecystectomy planned during the gastric bypass
  • history of bariatric surgery except gastric band and gastric balloon
  • history of type 1
  • treatment interfering with the cortisol metabolism: taking oral or inhaled within the last 6 months
  • treatment by BA as ursodeoxycholic acid, bile acids sequester, statin, fibrate stopped less than 4 weeks ago
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Obese/non-diabetic patients undergoing gastric bypass surgery

    Other: Blood and urine collection

Interventions

  • OtherBlood and urine collection

    Blood sampling urine collections before RYGP and 1 month and 1 year after.

06

What researchers measure

Primary outcomes

  1. Correlation between the variations of urinary cortisol metabolites and plasmatic total BA level before and after RYGB

    Time frame: At 1 year

Secondary outcomes

  1. Urinary cortisol metabolite profile modification

    Time frame: At 1 month after RYGP, at 1 year after RYGP

  2. Urinary and plasmatic BA profile modification

    Time frame: At 1 month after RYGP, at 1 year after RYGP

  3. Correlation between the variations of cortisol metabolites and the variations of metabolic parameters 1 year after gastric bypass

    Time frame: at 1 year

07

Study locations

1 of 1 sites recruiting
  • Hôpital Huriez - Service d'endocrinologie, diabétologie, nutrition et métabolisme
    Lille, France
    Recruiting
    • Stéphanie ESPIARD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 45 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2021
First posted
Apr 14, 2021
StartActual
Mar 30, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04844684
Responsible party
Sponsor
First posted
Apr 14, 2021
Start date
Mar 30, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Dec 23, 2025

Study contacts

Stéphanie ESPIARD, MD
Contact
stephanie.espiard@chru-lille.fr
0320445962 ext. +33
Stéphanie ESPIARD, MD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion